Kiniksa to Present Data on the Burden of Disease in Patients with Recurrent Pericarditis at the International Society for Pharmacoeconomics and Outcomes Research HAMILTON, Bermuda, May 16, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...

Kiniksa Presents Rilonacept Interim Phase 2 Clinical Data Poster at the American College of Cardiology’s 68th Annual Scientific Session - Interim clinical data show reductions in both inflammation and reported pain throughout the treatment period- Enrollment is ongoing in RHAPSODY, Kiniksa’s pivotal Phase 3 trial of rilonacept in...

Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical Trial - Phase 2 enrollment completed; interim clinical data show reductions in both inflammation and reported pain after first dose and throughout treatment period - Pivotal Phase 3 clinical trial,...